The Healthcare company, Quipt Home Medical (QIPT – Research Report), has received a rating update from a Wall Street analyst today. Analyst Bill Sutherland from Benchmark Co. remains bullish on the stock and has a $10.00 price target.
According to TipRanks.com, Sutherland is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.6% and a 38.3% success rate. Sutherland covers the Healthcare sector, focusing on stocks such as Clinigence Holdings, Surgery Partners, and Assure Holdings.
Currently, the analyst consensus on Quipt Home Medical is a Strong Buy with an average price target of C$12.31, a 50.3% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a C$12.75 price target.
Quipt Home Medical’s market cap is currently C$216.6M and has a P/E ratio of 29.49.
Protech Home Medical Corp provides in-home monitoring equipment, supplies and services to patients. The company’s services consist of Daily & Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea & PAP Treatment.
The company’s shares closed last Wednesday at C$8.23.
Read More on TSE:QIPT:
- Quipt Home Medical Reports Record Second Quarter Fiscal 2023 Financial Results Posting Revenue Growth of 73% and Adjusted EBITDA Growth of 86%
- Quipt Home Medical Corp (QIPT) Q2 Earnings Cheat Sheet
- Quipt Home Medical Announces Date and Time for Fiscal Q2 2023 Conference Call and Audio Webcast
- Quipt Home Medical receives conditional approval to graduate to TSX
- Quipt Home Medical Receives Conditional Approval to Graduate to the Toronto Stock Exchange
